Market experts recommend several stocks to buy today, 21 May 2026, amidst global uncertainties. These stock picks include ...

Sharekhan had an interaction with Laurus Labs management and their commentary was positive, pointing towards a robust growth ...

Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven ...

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Laurus Labs has seen a notable increase in its consensus analyst price target, which has risen from ₹724.14 to ₹815.86. This revision follows renewed analyst optimism, attributed largely to the ...

Revenue: INR1,570 crores, reflecting a 31% year-on-year growth. Gross Margin: 59%, an increase of more than 4% due to better product mix and process improvements. EBITDA: INR389 crores with a margin ...

Laurus Labs reports a 19% rise in Q4 net profit to ₹279 crore, driven by strong revenue growth and new launches.

ETHealthworld.com brings latest satyanarayana chava news, views and updates from all top sources for the Indian Health industry.

Gland Pharma jumped 15.85 per cent to Rs 2,164.40, while Sun Pharma climbed 1 per cent to Rs 1,896.90. Laurus Labs moved up 0 ...

When Dr Satyanarayana Chava started Laurus Labs in 2007, he invested nearly Rs 60 crore of his own money into it. His confidence in its success was neither bravado nor bluster, but defined by his ...

Hyderabad: Laurus Bio, a subsidiary of Hyderabad-based biopharma player Laurus Labs Ltd, has secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs ...